---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-000385"
form_type: "8-K"
ticker: "FEED"
cik: "0001326706"
company_name: "ENvue Medical, Inc."
filed_at: "2025-01-06T23:59:59+00:00"
generated_at: "2026-05-28T09:57:31.633533+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NanoVibronix completes UroShield pilot study; Nasdaq panel grants limited extension with conditions

## Summary
- Completed pilot phase of UroShield RCT at Univ. of Michigan; full trial to begin in 2025.
- Pilot focused on nursing home residents, studying reduction of UTIs, catheter blockages and pain.
- Nasdaq panel granted extension until March 31, 2025 to meet bid price and equity rules.
- Conditions: stockholder approval for reverse split by Feb 27, 2025; effect split and show $1.00 bid for 10 consecutive days.
- Must also demonstrate compliance with $2.5M stockholders' equity requirement; delisting risk remains.

## SEC filing metadata
- accession: 0001493152-25-000385
- form_type: 8-K
- ticker: FEED
- cik: 0001326706
- company_name: ENvue Medical, Inc.
- filed_at: 2025-01-06T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326706/000149315225000385/0001493152-25-000385-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326706/000149315225000385/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-000385
- JSON: https://secwatch.observer/filing/0001493152-25-000385.json
- Plain text: https://secwatch.observer/filing/0001493152-25-000385.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.